COMP <GO>
BMY vs MRK // PIOTROSKI F-SCORE QUALITY
Bristol-Myers Squibb Company (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BMY 4
— MRK 10
■ METRIC PARITY
LAST: $62.48 (+1.78%) • MKT CAP: $125.40B
piotroski-score
7/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMY VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMY | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.10% | 74.80% | -3.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.30% | 20.70% | -7.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 15.3x | +1.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 10.24% | 3.42% | +6.82 | BMY | /fcf-yield <GO> |
| Operating Margin | 17.90% | 34.30% | -16.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 14.60% | 28.10% | -13.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -0.20% | 1.30% | -1.50 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.02% | 2.26% | +1.76 | BMY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 5.19 | -2.95 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.7 | 56.9 | -2.15 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.92 | +0.06 | BMY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.6x | 18.4x | -1.80 | BMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $125.40B | $361.02B | -$235.62B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMY REV | MRK REV | BMY GROSS % | MRK GROSS % | BMY FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $48.19B | $65.01B | 71.1% | 74.8% | $12.85B | $12.36B |
| FY 2024 | $48.30B | $64.17B | 71.1% | 76.3% | $13.94B | $18.10B |
| FY 2023 | $45.01B | $60.12B | 44.0% | 44.0% | $11.83B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMY // BETA 0.98
MRK // BETA 0.92